Insights Corner
๐๐ฟ๐ถ๐ฑ๐ด๐ถ๐ป๐ด ๐ง๐๐ผ ๐ช๐ผ๐ฟ๐น๐ฑ๐: ๐๐ป๐๐ถ๐ด๐ต๐๐ ๐ณ๐ผ๐ฟ ๐๐๐ฝ๐ถ๐ฟ๐ถ๐ป๐ด ๐ฃ๐ฟ๐ผ๐ณ๐ฒ๐๐๐ถ๐ผ๐ป๐ฎ๐น๐ ๐ฎ๐ป๐ฑ ๐ฆ๐๐๐ฑ๐ฒ๐ป๐๐ ๐๐ผ๐ป๐๐ถ๐ฑ๐ฒ๐ฟ๐ถ๐ป๐ด ๐ง๐ฎ๐ถ๐๐ฎ๐ป
๐๐ฟ๐ถ๐ฑ๐ด๐ถ๐ป๐ด ๐ง๐๐ผ ๐ช๐ผ๐ฟ๐น๐ฑ๐: ๐๐ป๐๐ถ๐ด๐ต๐๐ ๐ณ๐ผ๐ฟ ๐๐๐ฝ๐ถ๐ฟ๐ถ๐ป๐ด ๐ฃ๐ฟ๐ผ๐ณ๐ฒ๐๐๐ถ๐ผ๐ป๐ฎ๐น๐ ๐ฎ๐ป๐ฑ ๐ฆ๐๐๐ฑ๐ฒ๐ป๐๐ ๐๐ผ๐ป๐๐ถ๐ฑ๐ฒ๐ฟ๐ถ๐ป๐ด ๐ง๐ฎ๐ถ๐๐ฎ๐ป https://abvcpharma.com/wp-content/uploads/2024/12/1734064660227.jpg 1068 783 ABVC https://secure.gravatar.com/avatar/fca8810fafc48ff205f8de427ddbfd02?s=96&d=mm&r=gAs someone who moved to Taiwan over 14 years ago to pursue higher studies and later transitioned into a fulfilling career, Iโm proud to represent the growing community of Indians working and living in Taiwan. My journey here has been one of learning, adaptation, and immense professional growth, and Iโm keen to share insights with aspirants back in India who are considering Taiwan as a destination for education and work. ๐ช๐ต๐ ๐ง๐ฎ๐ถ๐๐ฎ๐ป? Taiwan offers a unique combination of high-quality education, advanced research opportunities, and a thriving job market. With its world-class universities and cutting-edge industries, itโs an ideal place for…
Indian Talent in Taiwan
Indian Talent in Taiwan https://abvcpharma.com/wp-content/themes/movedo/images/empty/thumbnail.jpg 150 150 ABVC https://secure.gravatar.com/avatar/fca8810fafc48ff205f8de427ddbfd02?s=96&d=mm&r=gLots of Indians work and study in Taiwan! Dr. Priya is visiting some students and professionals currently working in Taiwan to see how they feel about their lives here. This episode highlights ABVC’s CEO Uttam Patil and some of our hardworking colleagues in our Taiwan office. https://www.youtube.com/watch?v=xLBStpD5BAI
All-Natural Treatment for Major Depressive Disorder (MDD) | ABV-1504
All-Natural Treatment for Major Depressive Disorder (MDD) | ABV-1504 https://abvcpharma.com/wp-content/themes/movedo/images/empty/thumbnail.jpg 150 150 ABVC https://secure.gravatar.com/avatar/fca8810fafc48ff205f8de427ddbfd02?s=96&d=mm&r=gABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine https://abvcpharma.com/wp-content/themes/movedo/images/empty/thumbnail.jpg 150 150 Press Release https://secure.gravatar.com/avatar/ccdf917cf35d7f34fb2fe57df9e6cb93?s=96&d=mm&r=gFREMONT, CA, March 19, 2024 ABVC BioPharma Inc., a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, proudly announced today that its CEO, Dr. Uttam Patil, was selected as one of the Top 10 CEOs in Taiwan 2024 byย CEO Insights Asia Magazine. This recognition is a testament to Dr. Patil’s outstanding leadership, innovative vision, and significant contributions to the Company. Dr. Patil is confident in the Company’s prospects, so he owns stock options without claiming a salary. Within his first year as the Company’s CEO, the Company saw a rise in the stock price of its common…
Summer 2024 Investor Presentation
View the latest product information, status updates, financial information, and more.
SAFE HARBOR STATEMENT
With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual future results of ABVC could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company’s operations, inability to hire and retain qualified personnel, and changes in the general economic climate. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by ABVC, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.
Investor Considerations
- Strong portfolio of medicines and medical devices addresses wide range of disorders.
- In 2022, Vitargus is expected to begin a global pivotal trial, the final step leading to marketing in collaboration with big pharma licensing partners.
- MDD drug intended to reduce adult depression completes Clinical Phase II with results exceeding expectations.
- Botanical expertise leads to medicines with fewer side effects.
- Partnerships with some of the most prestigious researchers in the world enhances the value of clinical trial results.
- Business model designed to minimize burn rate.
- Less than 30 million shares outstanding.
